bioAffinity Technologies Hosts CHEST Presentation on CyPath Lung Cancer Risk Assessment

bioAffinity Technologies will sponsor a CHEST 2026 presentation on October 21, 2026, at Phoenix Convention Center. Chief Medical Officer Gordon H. Downie will discuss CyPath Lung’s role in lung cancer risk assessment and pulmonary nodule management. The presentation will include preliminary research on an investigational test for asthma- and COPD-related lung inflammation. The Medical and Scientific Advisory Board will meet during the conference to review clinical programs, including CyPath Lung’s federal healthcare expansion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via (Ref. ID: 202610150800BIZWIRE_USPR_____20261015_BW646755) on October 15, 2026, and is solely responsible for the information contained therein. (C)